Equities research analysts expect Unity Biotechnology Inc (NASDAQ:UBX) to report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Unity Biotechnology’s earnings. The company is expected to issue its next earnings report on Thursday, November 8th.

On average, analysts expect that Unity Biotechnology will report full year earnings of ($1.19) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($1.58) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.38).

UBX has been the subject of several analyst reports. Zacks Investment Research upgraded Unity Biotechnology from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Wednesday, August 15th. Mizuho initiated coverage on Unity Biotechnology in a research report on Thursday, September 6th. They issued a “buy” rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.00.

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new position in Unity Biotechnology in the second quarter worth approximately $168,000. Citadel Advisors LLC purchased a new position in Unity Biotechnology in the second quarter worth approximately $230,000. Gilder Gagnon Howe & Co. LLC purchased a new position in Unity Biotechnology in the second quarter worth approximately $301,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Unity Biotechnology during the second quarter worth $309,000. Finally, Dean Capital Investments Management LLC purchased a new position in shares of Unity Biotechnology during the second quarter worth $543,000. Institutional investors own 30.25% of the company’s stock.

Shares of NASDAQ:UBX traded down $0.53 during midday trading on Friday, hitting $13.87. The company had a trading volume of 138,809 shares, compared to its average volume of 140,064. Unity Biotechnology has a twelve month low of $12.75 and a twelve month high of $24.56.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.

Featured Article: Trading Penny Stocks

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.